Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

ASH 2024 Summary: CLL Highlights

2024 ASH Annual Meeting Insights Hub

A. Danilov

ASH 2025 Review: Acalabrutinib + Venetoclax +/- Obinutuzumab vs. Che…

University of Colorado Division of Hematology

M. Kamdar

Year in Review 2024: CLL Highlights

The University of Kansas Cancer Center

M. Hoffmann

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

ASH 2024 Summary: Clinical Application of Practice-Changing Abstract…

2024 ASH Annual Meeting Insights Hub

K. Rogers, J. Woyach

ASH 2024 Insights: Ph 3 AMPLIFY - Fixed-Duration Acalabrutinib + Ven…

2024 ASH Annual Meeting Insights Hub

J. Brown

The Future of CLL Treatment: Combination Therapies, Overcoming Resis…

MyCancerHaven

R. Vij, A. Kittai

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

CLL in 2024: Evolution of the Role of Novel Targeted Therapies

Louisville Hematology Highlights

C. Coombs

Emerging Trends in the Treatment Landscape of CLL

Moffitt Cancer Center

J. Pinilla-Ibarz

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

Approach to Treatment Selection and Personalization in 1L CLL

Dima El-Sharkawi

Recent Updates on CLL Treatment Guidelines: Panel Member Insights

Roswell Park Comprehensive Cancer Center

M. Cortese

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

2025 Updates: Advances in CLL

Total Health

N. Jain

ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

BTK Inhibitors in CLL: Evolution & Frontline Use

MyCancerHaven

R. Vij, B. Fakhri

Current Guideline-Informed Treatment of CLL

Fred Hutchinson Cancer Center

C. Ujjani

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna